WebApr 3, 2024 · The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, without gene amplification) … WebJul 25, 2024 · DESTINY-Breast04 is a global, randomized, open-label, pivotal phase 3 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) versus physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel) in patients with HR positive or HR negative, HER2 low unresectable and/or metastatic breast cancer ...
Trastuzumab Deruxtecan in HER2-Low Breast Cancer NEJM
WebJan 25, 2024 · Trastuzumab Deruxtecan Stands Out for HER2+ and HER2-Low Breast Cancer Jan 25, 2024 Jessica Hergert Aditya Bardia, MD, MPH, discusses the clinical implications of the DESTINY-Breast03... WebJul 8, 2024 · In DESTINY-Gastric01, of the 125 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse events of heart ... dallas cowboys nfl gear
Cofepris aprueba trastuzumab deruxtecán en CMM HER2+ y HER2 …
WebMar 27, 2024 · DESTINY-Breast04 phase 3 trial first presented at the American Society of Clinical Oncology 2024 Annual Meeting and published in . The New England Journal of Medicine. ... unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior WebFeb 21, 2024 · In contrast, up to 55% of all patients with breast cancer have tumours with a HER2-low score, as defined in the DESTINY-Breast04 trial, and approval in this group could unlock $3 billion in... WebMay 8, 2024 · Efficacy was based on DESTINY-Breast04 (NCT03734029), a randomized, multicenter, open-label clinical trial that enrolled 557 patients with unresectable or … dallas cowboys nfl jerseys for sale